drugset
drugset / Trial / NCT04873869

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

NCT04873869 ↗

Phase 2 Terminated 8 enrolled Neurocrine Biosciences
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).

Timeline

Start
2022-01-31
Primary completion
2023-03-17
Completion
2023-03-17

Outcome

Outcome not reported

Stopped (Business): “This study was prematurely terminated due to sponsor decision.”

Drugs

EvaluationDrugModalityDoseRoute
Subject ZANDATRIGINE Small molecule — Oral

Indications

developmental and epileptic encephalopathy, 13